FDAnews Drug Daily Bulletin

BIOVAIL SHAREHOLDERS SLAP SAC, OTHERS WITH $4B SUIT

March 28, 2006
A A

About a month after Biovail Corp. filed a $6 billion action against 22 defendants, including hedge fund SAC Capital Management, its founder, Steven Cohen, and the research firm now known as Gradient Analytics, shareholders of the Canadian pharmaceutical have followed suit with their own $4 billion class action against basically the same group.
Institutional Investor